Download our new whitepaper, “Immune Reset,” for the latest insights
CAR-T therapy is expanding beyond oncology and showing potential to deliver durable remission in severe autoimmune disease. Our new whitepaper summarizes the emerging clinical signal and, more crucially, the practical requirements to deliver access, adoption, and real-world impact.
Developed by Lumanity’s subject matter experts in cell, gene, and nucleic acid therapeutics, this paper brings together clinical, operational, and market access perspectives to help teams move from early promise to scalable delivery.
What’s driving the momentum
Autoimmune CAR-T is increasingly being discussed through the lens of “immune reset”—a reframing that’s gaining traction as early data suggest the potential for deep responses in selected patients. But translating signal into standard-of-care adoption will require more than clinical excitement. It will require coordinated changes across:
- Safety protocols and risk management expectations
- Sites of care and operational readiness
- Referral pathways and patient identification
- Evidence planning, so access does not lag data generation
What you will learn
This whitepaper provides strategic insights into overcoming
the key barriers to adopting CAR-T therapy in autoimmune
disease, including:
- Need for improved therapeutic index
- Manufacturing capacity constraints
- Economic and real-world evidence hurdles
- Changing regulatory requirements and safety management
- Need for targeted healthcare professional education
How we can help
Lumanity helps life sciences teams cut through complexity and make confident decisions across medical, commercial, and regulatory priorities. We transform data into real world insights and evidence that support timely action for patients, providers, payers, and regulators.
Get your whitepaper
Complete the form to download a copy of the whitepaper
"*" indicates required fields
